High Levels of FGF11 Correlate with Poor Survival in Patients with Human Papillomavirus (HPV)-Positive Oropharyngeal Squamous Cell Carcinoma

Human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC) is associated with a favourable prognosis. It has therefore been suggested that treatment should be individualized and separated by HPV status. However, additional prognostic markers are still needed before treatment c...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2023, Vol.15 (7), p.1954
Main Authors: Flon, Caroline Haglund de, Haeggblom, Linnea, Holzhauser, Stefan, Kostopoulou, Ourania N, Zupancic, Mark, Dalianis, Tina, Munck-Wikland, Eva, Marklund, Linda, Näsman, Anders
Format: Article
Language:English
Subjects:
Biomarkers
Cancer
Care and treatment
Complications and side effects
FGF11
Gene expression
Genetic aspects
Health aspects
Human papillomavirus
Immunohistochemistry
Lymphatic system
Medical prognosis
Medicin och hälsovetenskap
Messenger RNA
Oropharyngeal cancer
Papillomavirus infections
Patients
Principal components analysis
Prognosis
Radiation therapy
Ribonucleic acid
Risk factors
RNA
Squamous cell carcinoma
survival
Throat cancer
tonsillar cancer
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC) is associated with a favourable prognosis. It has therefore been suggested that treatment should be individualized and separated by HPV status. However, additional prognostic markers are still needed before treatment can be individualized for this patient group. For this purpose, all patients diagnosed with HPV and p16-positive OPSCC in Stockholm 2000-2009, identified as having a partial/nonresponse to treatment and having viable tumour cells in their neck specimen with material available were categorized as cases. These were matched to controls (complete responders), and the differences in the gene expression were analysed. Two separate verification cohorts were identified including patients with HPV- and p16-positive OPSCC, and the data from the case-control study were verified by qPCR and immunohistochemistry (IHC) in the respective cohorts. A separation of gene expression in correlation with survival was observed in the case-control study, and FGF11 expression was identified as significantly differently expressed between the two groups. The prognostic role of FGF11 was validated in the two cohorts on the RNA and protein levels, respectively. Taken together, our findings suggest that FGF11 may indicate a poor prognosis in HPV-positive OPSCC and may serve as a prognostic biomarker.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers15071954